Association of Trimethadione Therapy and Myasthenia Gravis

Publisher Website
Google Scholar
Abstract
MYASTHENIA gravis is an uncommon disorder of unknown cause. Current evidence suggests that it may be related to abnormal immune mechanisms because of its frequent association with more clearly defined immunologic disorders.1 A patient in whom myasthenia gravis and trimethadione toxicity simultaneously developed during treatment for petit-mal epilepsy was recently studied. The known tendency for this drug to produce immunologic complications2 , 3 suggested that myasthenia gravis might also have resulted from the therapy and provides further evidence that myasthenia gravis may be associated with an abnormal immune state.Case ReportA 10-year-old girl (N.Y.H. 96–85–91) was first seen because of brief . . .

This publication has 4 references indexed in Scilit: